Vildagliptin-¹³C₅,¹⁵N  (Synonyms: 维格列汀-¹³C₅,¹⁵N; LAF237-¹³C₅,¹⁵N; NVP-LAF 237-¹³C₅,¹⁵N)

Vildagliptin-¹³C₅,¹⁵N (LAF237-¹³C₅,¹⁵N; NVP-LAF 237-¹³C₅,¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity^[1][2].

氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

309.36

C₁₂¹³C₅H₂₅N₂¹⁵NO₂

1044741-01-6

274901-16-5

维达列汀-¹³C₅,¹⁵N；维格列汀-¹³C₅,¹⁵N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.  [Content Brief]

  [2]. Villhauer EB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46(13):2774-89.  [Content Brief]

  [3]. Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64(2):226-35.  [Content Brief]